分子声波振动疗法在传染性病毒疾病治疗中的潜力分析
摘要
关键词
全文:
PDF参考
HoySM. Amubarvimab/Romlusevimab:First approval[J]. Drugs, 2022, 82(12):1327-1331.
CaoY, SongW, WangL, et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA. 2. 75[J]. Cell Host&Microbe, 2022, 30(11):1527-1539. e5.
CaoY, YisimayiA, JianF, et al. BA. 2. 12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection[J]. Nature, 2022, 608(7923):593-602.
李春梅,孙琦,陆阳彬.冠状病毒3CL蛋白酶活性调控机制及抑制剂研究[J]. 中国科学:化学,2020,50(10):1250-1279.
QuPK, EvansJP, FaraoneJL, et al. Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ. 1, BQ. 1. 1, BA. 4. 6, BF[J]. 7 and BA. 2. 75. 2. bioRxiv, 2022.
ZouL, RuanF, HuangM, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients[J]. N Engl J Med, 2020, 382(12):1177-1179.
MefsinY, ChenD, BondHS, et al. Epidemiology of infections with SARS-CoV-2 Omicron BA. 2 variant in Hong Kong, January-March 2022[J]. Emerg Infect Dis, 2022, 28(9):1856-1858.
ZhouF, YuT, DuR, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study[J]. Lancet, 2020, 395(10229):1054-1062.
MenniC, CristinaM, AnaM, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance:A prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335):1618-1624.
单思思,王若珂,张绮,等.安巴韦单抗注射液(BRII-196)及罗米司韦单抗注射液(BRII-198)[J].中国医药导刊,2022,24(1):2-8.
DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i12.22904
Refbacks
- 当前没有refback。

此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。